PHARMNOVO AIMS TO DEVELOP novel drugs with superior clinical properties to treat patients with chronic pain using our knowledge and experience of drug design and G protein-coupled receptor pharmacology. Our specific pharmacological target is the delta opioid receptor (DOR).
PharmNovo’s primary aim is to target the multiple disease areas of chronic neuropathic pain and the commonly associated conditions of anxiety and depression. However,there are other evidence-based therapeutic targets including migraine, pruritis (itch) and chronic cough. These disease areas have mechanistic commonalities susceptible to the company’s novel approach to drug discovery.
Given the complexity of chronic pain states we think it is impractical to attempt to produce a medicine that will treat all aspects of the various disease states and PharmNovo’s development strategy is focussed on sensory hypersensitivity conditions, such as mechanical allodynia and hyperalgesia, which are common and hard-to-treat components of many chronic neuropathic pain states. Theseconditions can be studied clinically with objective measures (quantitativesensory testing) as opposed to the more commonly applied subjective approachesused in trials of other chronic pain medicines.
Medicon Village AB
SE-223 81 Lund, Sweden